Claude

The Numbers

Everest Industries trades at ₹335 per share, 0.92x book value, with no meaningful P/E because TTM EPS is -₹29.55. The stock has fallen 55% from its 52-week high of ₹750. The single metric most likely to rerate or derate this stock is operating margin – if it recovers above 5%, the equity gets re-priced toward book value; if losses deepen further, book value itself erodes as equity gets consumed.

The Margin Collapse – The Chart That Explains Everything

Revenue and Earnings Power

Operating income has been cut by three-quarters from ₹113 Cr (FY2021) to ₹30 Cr (FY2025). Meanwhile depreciation has risen from ₹25 to ₹39 Cr as the Mysore plant was capitalised, and interest expense jumped from ₹4 to ₹24 Cr. The cost base has grown while revenue stagnated, compressing earnings to zero and beyond.

EPS peaked at ₹39.56 in FY2019 and has fallen to negative territory. The current TTM EPS of -₹29.55 reflects the accelerating deterioration in H1 FY2026.

Quarterly Deterioration

The seasonal pattern (Q2 monsoon weakness) is normal, but the magnitude is worsening. Q3 FY2026 posted a ₹19 Cr operating loss, the worst quarter in at least three years. Even the typically strong Q1 is weakening: Q1 FY2026 delivered ₹16 Cr versus ₹27 Cr in Q1 FY2025.

Q3 FY2026 EPS of -₹23.95 is alarming – it includes interest expense of ₹7 Cr and a pretax loss of ₹48 Cr on what appears to be a combination of weak volumes, margin compression, and possibly write-downs.

Cash Generation – The Real Problem

Cumulative FCF over the last 5 years (FY2021-FY2025) is -₹46 Cr. The business consumed cash even while revenues grew. FY2021's ₹248 Cr was an anomaly (COVID working capital release), not sustainable earnings power. The underlying cash generation is structurally weak.

Balance Sheet and Leverage

Shareholders' equity has stagnated at ₹597 Cr while total liabilities have grown from ₹930 Cr (FY2021) to ₹1,311 Cr (FY2025). The debt-to-equity ratio has worsened from 0.83x to 1.20x. As of Q2 FY2026, equity has eroded further to ₹577 Cr as losses consume retained earnings.

Interest coverage has crashed from 28x (FY2021) to 1.25x (FY2025). At TTM level, operating income is negative, meaning the company cannot cover interest from operations. This is the balance sheet stress signal – sustained losses will force either equity dilution or asset sales.

Working Capital Efficiency

The cash conversion cycle has nearly doubled from 68 days (FY2021) to 128 days (FY2025). The deterioration is driven by two forces: inventory days remain elevated at 154 (vs. 142 at peak efficiency), and payable days have contracted from 92 to 59, suggesting suppliers are demanding faster payment as the company's financial position weakens.

Peer Comparison – Where Everest Stands

Ramco Industries is the most instructive comparison: comparable revenue scale (₹1,632 Cr vs. ₹1,707 Cr) but 4.4x the market cap, because Ramco earns 11% operating margin vs. Everest's 2%. Ramco's P/B is only 0.53x – also below book – but it generates positive ROCE and sustainable earnings. The valuation gap is purely an operating efficiency gap.

The margin gap with Ramco has widened from 7pp (FY2021) to 9pp (FY2025). Even Visaka, which also faces industry headwinds, maintains margins 3.5x higher than Everest. This suggests Everest's margin problem is company-specific, not purely cyclical.

Equity Erosion and Book Value at Risk

Equity peaked at ₹598 Cr in FY2024 and has begun shrinking. As of Q2 FY2026, it stands at ₹577 Cr – a ₹20 Cr decline in six months. At the current burn rate (TTM loss of ~₹47 Cr), book value per share is falling by roughly ₹30 per year. Today's 0.92x P/B may not provide downside protection if the book itself is deteriorating.

What Recovery Would Look Like

At 5% OPM on ₹1,800 Cr revenue (base recovery), the stock would trade at ~13x earnings – reasonable for an Indian building materials company. At Ramco-level margins (11%), EPS would be ₹80 and the stock would be trading at just 4.2x. The asymmetry is real, but requires an operating turnaround that the last four years have provided no evidence of.

What the Numbers Confirm, Contradict, and Demand

The numbers confirm Warren's thesis: this is a structurally challenged business earning sub-cost-of-capital returns, trading below book for good reason. The margin decline is not cyclical – peers have stabilised while Everest continues to deteriorate. Interest coverage at 1.25x is a genuine stress signal.

The numbers contradict any simple "deep value" thesis. Sub-book valuation is not a floor when the book itself is shrinking at ₹20 Cr per half-year. Cumulative free cash flow over 5 years is negative. The 0.75% dividend yield offers no meaningful return while waiting.

Watch next quarter: Q4 FY2026 results (due May-June 2026) will show whether the seasonal Q4 recovery materialises and whether operating margins can reclaim positive territory. If Q4 operating income fails to exceed ₹15 Cr, the full-year FY2026 loss will be deep enough to make the balance sheet conversation urgent.